Company / Return on Equity (ROE)
IGC Pharma, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-112.5%
FY2025
5-year range
-112.5% / -26.9%
FY2021-FY2025
Trend
-45.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
IGC Pharma, Inc. reports negative total equity of -112.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-112.5% in FY2025 with a 5-year CAGR of -100.3%.
Declined from -62.8% to -112.5% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -85.7pp
- 5-Year Change
- -100.3pp
- 10-Year Change
- -
Key checks
Key Insights
- IGC Pharma, Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 45.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -13.04 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -112.5% | -45.8% |
| FY2024 | -77.2% | -22.8% |
| FY2023 | -62.8% | -134.0% |
| FY2022 | -26.9% | +2.6% |
| FY2021 | -27.6% | -126.0% |
| FY2020 | -12.2% | +44.9% |
| FY2019 | -22.1% | +4.3% |
| FY2018 | -23.2% | +39.3% |
| FY2017 | -38.2% | -11.4% |
| FY2016 | -34.2% | -61.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026